BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to ...

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective raised by Scotiabank from $78.00 to $80.00 in a research report sent to investors on Thursday,Benzinga reports. They ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...